$WLKP

WOELFEL RANDY sold (to issuer) $107K of WLKP

WOELFEL RANDY sold (to issuer) 5,005 shares of Westlake Chemical Partners LP (WLKP) at $21.35 ($0.11M total) on 2026-08-06.

Original reporting
SEC EDGAR · WOELFEL RANDY
Published Aug 7, 2026, 11:34 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$WLKP
Neutral
high confidence
Mentioned
$WLKP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WLKPNeutralLow
01

Why it matters

The newest fact is the reported sale to the issuer of 5,005 shares at $21.3500 on 2026-08-06, with holdings after transaction of 23,913 shares.

02

Market read

Traders may note insider activity, but there is no accompanying fundamental update, guidance change, or corporate action beyond the transaction itself.

03

What to watch

Insider sales can be driven by liquidity needs, tax planning, or standardized issuer buyback mechanics; the filing provides no rationale or linkage to performance.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-07 after-hours/early session window (Form 4 timestamp)

Background

The article is a SEC Form 4 insider transaction disclosure for Westlake Chemical Partners LP (WLKP).

Company-level read

Ticker impact

$WLKPNeutralHigh confidence
Context

Westlake Chemical Partners LP disclosed an insider sale to the issuer of 5,005 shares at $21.3500 on 2026-08-06 via Form 4.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing is an insider sale to the issuer (buyback participation style) with no 10b5-1 plan and no accompanying operational or financial update.

Market effects

Minimal, as the disclosure is company-specific insider trading without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The lack of a stated 10b5-1 plan could be interpreted as discretionary selling, but the transaction is explicitly a sale to the issuer, which often reduces interpretive weight.

Key entities

  • Westlake Chemical Partners LP

    Subject of the Form 4 insider transaction disclosure (WLKP).

  • WOELFEL RANDY

    Director who sold shares to the issuer under code D.

Related articles

$WLKPMed

Westlake Chemical Partners LP (WLKP): Results of Operations and Financial Condition

Westlake Chemical Partners LP (WLKP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991_20260630earningsrele.htm EX-99.1 Document EXHIBIT 99.1 WESTLAKE CHEMICAL PARTNERS LP Contact—(713) 585-2900 Investors—Jonathan Baksht Media—L. Benjamin Ederington Westlake Chemical Partners LP Announces Second Quarter 2026 Results • Declared quarterly distribution

$WLKPMedAI 8/10

Westlake Chemical Partners LP Announces Second Quarter 2026 Results

Westlake Chemical Partners LP (NYSE: WLKP) reported Q2 2026 net income attributable to the partnership of $14.2 million, or $0.40 per limited partner unit, versus $14.6 million in Q2 2025. Operating cash flow was $129.8 million. It declared a $0.4714 per unit distribution, 48th consecutive quarter, with trailing twelve-month coverage of 1.04x. Credit facilities were amended to extend maturities to July 2031.